Abstract
Separation of 225Ra (t1/2 = 15 d) from its daughter isotope 225Ac (t1/2 = 10 d) is necessary to obtain pure 225Ac for cancer alpha-therapy. In this study, microscale separation of 225Ra from its daughter 225Ac using BioRad AG50X4 cation exchange resin was achieved with good reproducibility across microdevices, and ≥90% purity was achieved for 225Ac, which is comparable to conventional chromatography. These results indicate the potential for greater use of microfluidics for biomedical radiochemistry. The modularity of the system and its compatibility with different resins allows for quick and easy adaptation to the various needs of a separation campaign.
Original language | English |
---|---|
Pages (from-to) | 1994-2002 |
Number of pages | 9 |
Journal | Separation Science and Technology (Philadelphia) |
Volume | 54 |
Issue number | 12 |
DOIs | |
State | Published - Aug 13 2019 |
Funding
This work was supported in part by the DOE Office of Nuclear Physics, Isotope program, and by the Laboratory Directed Research and Development Program of Oak Ridge National Laboratory. ORNL is managed by UT-Battelle, LLC, for the U.S. Department of Energy under contract [DE-00OR22725]. Research on the development of microfluidic devices for radioisotope separations was sponsored by the Laboratory Directed Research and Development Program of Oak Ridge National Laboratory, managed by UT-Battelle, LLC, for the U. S. Department of Energy and the production of 225Ra and 225Ac used in these studies was supported by the DOE Office of Nuclear Physics, Isotope Program, under contract DE-00OR22725 with UT Battelle, LLC.
Keywords
- Actinium-225
- Ion chromatography
- Microfluidics
- Radium-225
- Targeted-Alpha-Therapy